Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2013-02-19 Regulatory Filings
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
THERAVANCE, INC. 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes a press release about the acceptance of a New Drug Application (NDA) by the FDA and validation of a Marketing Authorization Application (MAA) by the EMA. It includes no financial statements or detailed financial data, but rather an announcement of a significant corporate event. The document length is 3182 characters, which is relatively short and mainly references a press release attached as an exhibit. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Earnings Release or Annual Report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2013-02-19 English
Major Shareholding Notification 2013
Major Shareholding Notification
2013-02-14 English
THRX13GAMEND6
Major Shareholding Notification
2013-02-13 English
THERAVANCE, INC. 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 12, 2013, reporting Theravance, Inc.'s financial results for the quarter ended December 31, 2012. The text states that the information is being furnished and includes a press release as Exhibit 99.1. The document is relatively short (2753 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the 'MENU VS MEAL' rule, such a document is an announcement of a report (the press release) rather than the full earnings release report. Therefore, the appropriate classification is Earnings Release (ER), as it is the initial announcement of quarterly financial results.
2013-02-12 English
FORM 4 -
Director's Dealing
2013-02-12 English
FORM 4 -
Director's Dealing
2013-02-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.